TY  - JOUR
AU  - Ramalingam, Suresh S
AU  - Vansteenkiste, Johan
AU  - Planchard, David
AU  - Cho, Byoung Chul
AU  - Gray, Jhanelle E
AU  - Ohe, Yuichiro
AU  - Zhou, Caicun
AU  - Reungwetwattana, Thanyanan
AU  - Cheng, Ying
AU  - Chewaskulyong, Busyamas
AU  - Shah, Riyaz
AU  - Cobo, Manuel
AU  - Lee, Ki Hyeong
AU  - Cheema, Parneet
AU  - Tiseo, Marcello
AU  - John, Thomas
AU  - Lin, Meng-Chih
AU  - Imamura, Fumio
AU  - Kurata, Takayasu
AU  - Todd, Alexander
AU  - Hodge, Rachel
AU  - Saggese, Matilde
AU  - Rukazenkov, Yuri
AU  - Soria, Jean-Charles
AU  - FLAURA Investigators
PY  - 2019
DO  - 10.1056/NEJMoa1913662
UR  - http://hdl.handle.net/10668/14719
T2  - The New England journal of medicine
AB  - Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. A phase 3 trial compared first-line...
LA  - en
KW  - Acrylamides
KW  - Aged
KW  - Aniline Compounds
KW  - Antineoplastic Agents
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Double-Blind Method
KW  - ErbB Receptors
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - Gefitinib
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Proportional Hazards Models
KW  - Protein Kinase Inhibitors
TI  - Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
TY  - research article
VL  - 382
ER  -